HAPRPforKneeOA

Combination of hyaluronic acid and platelet-rich plasma injection therapy for knee osteoarthritis (double blinded randomized controlled trial) - HA and PRP injection for knee OA

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTb020200036

Enrollment

Registered

2020-12-25

Start date

2021-02-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis knee osteoarthritis, platelet rich plasma, hyaluronic acid

Interventions

To devide the candidate patients into 3 groups according to following material and to inject each material into affected knee joint 5 times everyweek. 1) 2.5ml of hyarulonic acid and 4ml of saline (HA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Prior written informed consent was obtained 2) Diagnosed with knee osteoarthritis 3) Age from 20 to 80 4) Kellgren-Lawrence grade 2 or 3 5) Possible to take MRI for exclusion of other diseases before treatment. 6) Need unilateral knee treatment with visual analog scale (VAS) pain on severe knee more than 40 and that of the other less than 40 7) Possible to visit hospital at all observational points ( considering Covid-19 pandemic, follow-up visit is substitutable for telephone consultiing ) 8) Good general condition

Exclusion criteria

Exclusion criteria: 1) Coagulopathy (Platlet 150,000/micro litter) 2) Anemia (Hb less than 9.0g/dl) 3) Systemic infection 4) Intake of anti-coagulant or anti-platelet drugs 5) Intake of non-steroidal anti-inflammatory drugs within 2 weeks 6) Taking hyaluronic acid injection into the target knee within 1 month 7) Steroid treatment regardless of root of administration within 3 months 8) PRP injection into the target knee within 1 year 9) Past history of knee surgery within 1 year 10) Those who are judged to be inappropreate by doctors who perform the regenerative medicine for any reason

Design outcomes

Primary

Measure	Time frame
Patient based outcome KOOS: Knee injury and Osteoarthritis Outcome score	—

Secondary

Measure	Time frame
existence of hydrarthrosis, Knee pain VAS, EQ-5D, hydrarthrosis and inflammatory findings, proteome analysis and inflammatory cytokine of joint fluid collected before injection, Complete blood count and proteome analysis of surplus PRP.	—

Countries

Japan

Contacts

Public ContactJunko Narita

Hirosaki University Graduate School of Medicine

a-z2000j@hirosaki-u.ac.jp+81-172-39-5083

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026